Latest David Krause Stories

PHILADELPHIA, Feb. 18 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced the addition of two executives to its senior management team. David Krause, M.D., F.A.C.P., has joined as Chief Medical Officer and Thomas C. Wicks, Ph.D., has joined as Vice President Global Regulatory Affairs. Tarsa's unique, once-daily oral form of calcitonin is in a global Phase III trial for the treatment of post-menopausal osteoporosis. David Brand, President and CEO of Tarsa noted, "We are fortunate to...